| Dr Ryan Edward Rebowe, MD | |
|
3700 Dauphin St Ste A, Mobile, AL 36608-1725 | |
| (251) 340-6600 | |
| (251) 479-7164 |
| Full Name | Dr Ryan Edward Rebowe |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 11 Years |
| Location | 3700 Dauphin St Ste A, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508203456 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 37757 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Park Clinic For Cosmetic And Reconstructive Surgery, P.c. | 2466513064 | 3 |
News Archive
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
The Associated Press: "Some lawmakers have suggested that a separate bill with changes that are supported by Republicans and Democrats would be one route toward progress on the health care overhaul. But a member of the Senate Finance Committee, Democratic Sen. Kent Conrad of North Dakota, says he doesn't see how lawmakers could get two health care bills through Congress and coordinate them well." Conrad spoke on CBS' "Face The Nation" (8/23).
New research into how a common parasite infection alters human behavior could help development of treatments for schizophrenia and other neurological disorders.
EpiCept Corporation today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
› Verified 3 days ago
| Entity Name | The Park Clinic For Cosmetic And Reconstructive Surgery, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821246869 PECOS PAC ID: 2466513064 Enrollment ID: O20081201000528 |
News Archive
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
The Associated Press: "Some lawmakers have suggested that a separate bill with changes that are supported by Republicans and Democrats would be one route toward progress on the health care overhaul. But a member of the Senate Finance Committee, Democratic Sen. Kent Conrad of North Dakota, says he doesn't see how lawmakers could get two health care bills through Congress and coordinate them well." Conrad spoke on CBS' "Face The Nation" (8/23).
New research into how a common parasite infection alters human behavior could help development of treatments for schizophrenia and other neurological disorders.
EpiCept Corporation today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Edward Rebowe, MD 3700 Dauphin St Ste A, Mobile, AL 36608-1725 Ph: (251) 340-6600 | Dr Ryan Edward Rebowe, MD 3700 Dauphin St Ste A, Mobile, AL 36608-1725 Ph: (251) 340-6600 |
News Archive
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
The Associated Press: "Some lawmakers have suggested that a separate bill with changes that are supported by Republicans and Democrats would be one route toward progress on the health care overhaul. But a member of the Senate Finance Committee, Democratic Sen. Kent Conrad of North Dakota, says he doesn't see how lawmakers could get two health care bills through Congress and coordinate them well." Conrad spoke on CBS' "Face The Nation" (8/23).
New research into how a common parasite infection alters human behavior could help development of treatments for schizophrenia and other neurological disorders.
EpiCept Corporation today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.
The national #KnowBetterDoBetter movement led by the Black AIDS Institute (BAI) is coming to Los Angeles, CA and the message is loud and clear- we can end the AIDS epidemic if we fully engage non-medical workers on the frontline of the battle with greater knowledge and skills.
› Verified 3 days ago
Stephen R Sheppard, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 Memorial Hospital Drive, Suite 309, Mobile, AL 36608 Phone: 251-344-1151 Fax: 251-344-2113 | |
Daniel A Dennis Iii, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-435-5114 | |
Charles L Dyas Jr., M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2860 Dauphin St, Suite A, Mobile, AL 36606 Phone: 251-471-3211 Fax: 251-471-3475 |